DelveInsight’s “Menkes Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Menkes Disease, historical and forecasted epidemiology as well as the Menkes Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Menkes Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Menkes Disease Market Forecast
Some of the key facts of the Menkes Disease Market Report:
-
The Menkes Disease market size was valued ~USD 8 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
In December 2023, Sentynl Therapeutics, Inc. (Sentynl), a biopharmaceutical company based in the U.S. and fully owned by Zydus Lifesciences, Ltd. (Zydus Group), has announced the signing of an Assignment and Assumption Agreement with Cyprium Therapeutics, Inc. (Cyprium), a subsidiary of Fortress Biotech, Inc. (Nasdaq: FBIO). As part of this agreement, Cyprium has successfully transferred its global proprietary rights and U.S. FDA documentation related to CUTX-101, a copper histidinate candidate for treating Menkes disease, to Sentynl.
-
The Standard of Care accounted for the entire market, which was valued at approximately USD 7.9 million in 2023 across the 7MM.
-
According to our assessment, there were approximately 177 diagnosed prevalent cases of Menkes Disease in the 7MM in 2023, with expectations for these numbers to rise by 2034. The US had the highest number of cases.
-
Among European countries in 2023, France had the highest diagnosed prevalent cases of Menkes Disease at 26%, followed by Germany and the UK, each with 24%. Conversely, Spain had the lowest diagnosed prevalence, accounting for 11%.
-
In 2023, the US represented the largest share of diagnosed Menkes disease cases in the 7MM, with 54%, followed by Japan, which accounted for approximately 11%. Among European countries, France had the highest number of cases, representing about 9% of the total 7MM cases.
-
In 2023, France held the largest market share in the EU4 and UK region with 27%, while Spain had the smallest share at 12%.
-
The 7MM treatment market currently lacks an approved targeted therapy for Menkes Disease. However, with the anticipated launch of CUTX-101 by 2025, the market is expected to see significant growth.
-
Key Menkes Disease Companies: Cyprium Therapeutics and Sentynl Therapeutics, Cyprium Therapeutics, Inc., and others
-
Key Menkes Disease Therapies: CUTX-101, Copper Histidinate, and others
-
The Menkes Disease epidemiology based on gender analyzed that Menkes Disease usually affects male neonates through unaffected carrier women. It may occurs in females, related to unusual genetic circumstances
-
The Menkes Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Menkes Disease pipeline products will significantly revolutionize the Menkes Disease market dynamics.
Menkes Disease Overview
Menkes disease is a rare genetic disorder caused by a mutation in the ATP7A gene, which is responsible for copper transport in the body. This condition leads to severe copper deficiency, affecting the body’s ability to utilize copper effectively. Symptoms often appear in infancy and may include poor growth, developmental delays, neurological problems, and distinctive hair abnormalities (often described as “kinky” or “curly” hair). Menkes disease is typically fatal in early childhood without treatment. Management options include copper histidinate injections and supportive care, though outcomes can vary significantly.
Get a Free sample for the Menkes Disease Market Report:
https://www.delveinsight.com/report-store/menkes-disease-market
Menkes Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Menkes Disease Epidemiology Segmentation:
The Menkes Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Menkes Disease
-
Prevalent Cases of Menkes Disease by severity
-
Gender-specific Prevalence of Menkes Disease
-
Diagnosed Cases of Episodic and Chronic Menkes Disease
Download the report to understand which factors are driving Menkes Disease epidemiology trends @ Menkes Disease Epidemiology Forecast
Menkes Disease Therapies and Key Companies
-
Copper Histidinate: Cyprium Therapeutics, Inc.
-
CUTX-101: Cyprium Therapeutics and Sentynl Therapeutics
Menkes Disease Market Drivers
-
Submission of NDA of CUTX-101
-
Increasing awareness among families who have a history of Menkes
-
Parents of affected babies understand the rarity of the disease and allow their children to be a part of the trial
-
Ongoing development of screening techniques
-
Ongoing development of gene therapy
Menkes Disease Market Barriers
-
Clinical challenges in the early diagnosis of disease
-
Inability to trace the carrier mother
-
Insufficient number of studies to estimate the exact number of Menkes patients
-
Insufficient number of researches for the treatment of Menkes disease
Menkes Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Menkes Disease market or expected to get launched during the study period. The analysis covers Menkes Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Menkes Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major Menkes Disease market share @ Menkes Disease Treatment Market
Scope of the Menkes Disease Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Menkes Disease Companies: Cyprium Therapeutics and Sentynl Therapeutics, Cyprium Therapeutics, Inc., and others
-
Key Menkes Disease Therapies: CUTX-101, Copper Histidinate, and others
-
Menkes Disease Therapeutic Assessment: Menkes Disease current marketed and Menkes Disease emerging therapies
-
Menkes Disease Market Dynamics: Menkes Disease market drivers and Menkes Disease market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Menkes Disease Unmet Needs, KOL’s views, Analyst’s views, Menkes Disease Market Access and Reimbursement
To know more about Menkes Disease companies working in the treatment market, visit @ Menkes Disease Clinical Trials and Therapeutic Assessment
Table of Contents
1. Menkes Disease Market Report Introduction
2. Executive Summary for Menkes Disease
3. SWOT analysis of Menkes Disease
4. Menkes Disease Patient Share (%) Overview at a Glance
5. Menkes Disease Market Overview at a Glance
6. Menkes Disease Disease Background and Overview
7. Menkes Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Menkes Disease
9. Menkes Disease Current Treatment and Medical Practices
10. Menkes Disease Unmet Needs
11. Menkes Disease Emerging Therapies
12. Menkes Disease Market Outlook
13. Country-Wise Menkes Disease Market Analysis (2020–2034)
14. Menkes Disease Market Access and Reimbursement of Therapies
15. Menkes Disease Market Drivers
16. Menkes Disease Market Barriers
17. Menkes Disease Appendix
18. Menkes Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/